Peptides for Menopause: What the Evidence Actually Supports (and What It Doesn’t)

Peptides are being marketed to midlife women with an urgency that outpaces the science behind them. Scroll through any longevity podcast, wellness clinic menu, or Instagram feed and you’ll find stacks promoted for menopausal body composition, sleep, libido, skin, recovery, and metabolic health — often without a single mention of evidence level, FDA status, or the metabolic foundation these compounds depend on.

As Jackie Giannelli, a board-certified nurse practitioner at Mount Sinai’s Carolyn Rowan Center for Women’s Health, told The 19th: women in perimenopause are “willing to try anything to not feel bad” — and they’re being marketed to accordingly. But the most credible clinicians treating menopausal women are saying the same thing: optimize your hormones and your metabolic foundation first. Then — and only then — consider peptides for menopause as a targeted, monitored adjunct.

Here’s what the evidence actually shows for each of the most commonly marketed compounds.

CJC-1295 / Ipamorelin: Body Composition and Sleep

What it claims to do: This combination stimulates growth hormone (GH) release through two complementary pathways. CJC-1295 provides sustained GH elevation; Ipamorelin adds acute pulsatile spikes. The pitch for menopausal women centers on fat loss, muscle preservation, improved sleep quality, and skin health — all driven by elevated GH and IGF-1.

What the evidence shows: Pharmacokinetic studies confirm that CJC-1295 produces dose-dependent, sustained increases in GH and IGF-1 in healthy adults. However, no published, large-scale, randomized controlled trials have evaluated this combination for body composition, sleep, or anti-aging outcomes in menopausal women — or in any population.

What you need to know: Both compounds are classified by the FDA as Category 2 bulk drug substances, meaning they carry safety concerns that preclude standard compounding. Immunogenicity (potential for anaphylaxis), cardiovascular effects, and cancer risk from elevated IGF-1 are flagged concerns. Both are on the WADA Prohibited List. They remain available through some clinics due to ongoing legal challenges to FDA enforcement.

The metabolic context: GH affects body composition and RMR — both directly measurable by breath testing. If CJC-1295/Ipamorelin is genuinely improving lean mass and metabolic rate, a PNOĒ test should show it. Without that data, you’re relying on subjective impressions.

BPC-157: Recovery and Gut Health

What it claims to do: BPC-157 (Body Protection Compound-157) is marketed for accelerated tissue repair, gut lining restoration, and reduced inflammation. For menopausal women, it’s often positioned as support for joint pain, slower recovery, and gut dysfunction — all common perimenopausal complaints.

What the evidence shows: Over 35 animal studies demonstrate BPC-157’s ability to promote angiogenesis, stimulate collagen synthesis, and modulate inflammatory pathways across various injury models. However, a 2025 systematic review found only one human clinical study: a retrospective case series of 12 patients receiving intra-articular injections for knee pain. A separate pilot study assessed tolerability in just two healthy adults. No randomized controlled trials exist.

What you need to know: BPC-157 is FDA Category 2 and on the WADA Prohibited List. Quality control in the online and compounding market is inconsistent. The gap between “promising in rats” and “proven in humans” remains one of the widest in the peptide space.

The metabolic context: Tissue repair depends on adequate blood flow, oxygen delivery, and cellular energy — all of which are compromised when VO2 Max is low and metabolic health is poor. Measuring cardiovascular fitness and fat oxidation before pursuing a recovery peptide tells you whether your body’s own repair systems need optimization first.

GHK-Cu: Skin, Collagen, and Anti-Aging

What it claims to do: GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is marketed for collagen stimulation, wrinkle reduction, skin firmness, and wound healing. For menopausal women losing up to 30% of their collagen in the first five years after menopause, the appeal is obvious.

What the evidence shows: GHK-Cu has the most robust clinical evidence of any peptide in this list — for topical application. Multiple placebo-controlled studies in women aged 40–65 have demonstrated that topical GHK-Cu creams improve skin laxity, firmness, density, and thickness, reduce fine lines and wrinkle depth, and stimulate keratinocyte proliferation after 12 weeks of use. A 2023 clinical trial found a 28% average increase in skin collagen density after three months of daily topical application. An earlier study of 71 women with photoaging showed measurable improvements across multiple skin parameters.

What you need to know: The clinical data is specifically for topical formulations. Injectable GHK-Cu — which achieves tissue concentrations 10–20x higher than topical — changes gene expression at a deeper level, and long-term safety data for this route is lacking. As the Mount Sinai clinician noted: “We don’t have any good, long-term, randomized control, gold standard data to prove that injectable GHK-Cu is safe.”

The metabolic context: Collagen synthesis is an energy-intensive process that depends on adequate mitochondrial function, nutrient delivery, and hormonal support. Women with poor metabolic health may see reduced benefits from any collagen-stimulating intervention — topical or otherwise.

PT-141 (Bremelanotide): Libido and Sexual Desire

What it claims to do: PT-141 activates melanocortin receptors in the hypothalamus to stimulate sexual desire at a neurological level — unlike PDE5 inhibitors (Viagra/Cialis) which work on blood flow. It’s marketed to menopausal women experiencing low libido and hypoactive sexual desire disorder (HSDD).

What the evidence shows: PT-141 is FDA-approved (brand name Vyleesi) for HSDD in premenopausal women — making it the only peptide on this list with any FDA-approved indication in women. Clinical trials demonstrated statistically significant improvement in desire scores. It is used off-label for postmenopausal women, though efficacy data in this population is more limited.

What you need to know: PT-141 is administered via subcutaneous injection 45 minutes before sexual activity. Common side effects include nausea (in up to 40% of patients), flushing, and headache. It is contraindicated in women with uncontrolled hypertension or cardiovascular disease — which is particularly relevant during menopause, when cardiovascular risk increases significantly.

The metabolic context: Sexual function is downstream of vascular and metabolic health. VO2 Max, insulin sensitivity, and cardiovascular fitness all influence arousal and desire. A breath test that reveals poor cardiovascular health would suggest addressing the metabolic foundation before — or alongside — peptide therapy.

GLP-1s: The Strongest Evidence Base

What they claim to do: GLP-1 receptor agonists (semaglutide, tirzepatide) suppress appetite, improve glycemic control, and produce significant weight loss. For menopausal women, they’re increasingly used to address the metabolic syndrome, insulin resistance, and visceral fat accumulation that accompany estrogen decline.

What the evidence shows: GLP-1s have the most robust clinical evidence of any compound on this list — by a wide margin. FDA-approved for obesity and type 2 diabetes, with demonstrated cardiovascular and renal benefits. Average weight loss of 15–20% in clinical trials. Early research suggests GLP-1s may be more effective when combined with estradiol-based hormone therapy. However, up to 40% of weight lost can be lean mass, making metabolic monitoring essential.

What you need to know: GLP-1s are prescription medications, not compounded peptides. They require clinical supervision, and the muscle loss concern makes resistance training and protein intake non-negotiable during therapy. Metabolic testing before, during, and after GLP-1 use reveals whether the weight loss is genuinely improving health — or just shrinking a number on the scale.

The metabolic context: This is where PNOĒ testing is most directly relevant. RMR tracking detects muscle loss. VO2 Max monitoring ensures cardiovascular fitness is improving. Fat oxidation data confirms the body is becoming metabolically healthier, not just lighter.

The Hierarchy That Matters: Foundation Before Peptides

The most credible voices in menopause medicine — from Mount Sinai’s Giannelli to board-certified physicians publishing evidence reviews — converge on the same framework:

Step 1: Hormonal optimization. Evaluate and, when appropriate, initiate hormone therapy (estrogen, progesterone, testosterone). Assess thyroid function, cortisol patterns, and insulin sensitivity.

Step 2: Lifestyle foundations. Consistent strength training (essential for preserving muscle and bone during menopause). Adequate protein. Quality sleep. Stress management. These are non-negotiable — and they are measurable through metabolic testing.

Step 3: Metabolic assessment. Before adding any compound — peptide, supplement, or medication — know your baseline. What is your VO2 Max? Your RMR? Your fat oxidation rate? Your metabolic flexibility? These markers tell you what’s actually broken and what to prioritize.

Step 4: Targeted, monitored peptide use — if appropriate. Under clinical supervision. Through regulated pharmacies. Cycled for specific reasons. With metabolic data to verify it’s working.

Peptides aren’t the enemy. Guessing is.

A Note on the Regulatory Landscape

The peptide regulatory environment is shifting rapidly. In February 2026, HHS Secretary Kennedy announced that approximately 14 of the 19 peptides placed on the FDA’s Category 2 restricted list in 2023 — including BPC-157, Ipamorelin, GHK-Cu, and MOTS-c — are expected to return to Category 1, restoring the legal pathway for licensed compounding pharmacies to prepare them under physician prescription. CJC-1295’s status remains disputed due to reported cardiac side effects. As of this writing, the formal FDA publication has not yet been released. Category 1 status does not mean FDA approval — it means compounding eligibility with a valid prescription. These compounds still lack standardized dosing, large-scale human trials, and formal clinical indication approval. When access resumes, the same principle applies: work with a licensed clinician, use a regulated pharmacy, and test your metabolic baseline before starting any protocol.

The Bottom Line

Menopause is a metabolic event — not just a hormonal one. Peptides that claim to address its consequences can only work if the metabolic system they depend on is functional. Most women pursuing peptide protocols haven’t tested their VO2 Max, RMR, or fat oxidation rate. That’s the blind spot — and it’s the most important thing to fix before anything else.

A single breath test measures the metabolic foundation that every intervention depends on. Start there.

SOURCES

1. The 19th — “Making Sense of Peptide Mania” (April 2026): https://menopause.19thnews.org/p/making-sense-of-peptide-mania
2. Bonza Health — “Peptides in Perimenopause: A Physician’s Cautiously Curious Perspective” (2025): https://www.bonzahealth.com/blog/peptides-in-perimenopause-a-physicians-cautiously-curious-perspective
3. WomenHealth1 — “Menopause and Peptides in 2026” (2026): https://www.womenhealth1.com/menopause-and-peptides-in-2026-what-actually-helps-what-to-skip-and-what-to-ask-before-you-start/
4. PMC — “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration”: https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
5. EurekAlert / Yuvan Research — “Epigenetic mechanisms activated by GHK-Cu increase skin collagen density in clinical trial” (2023): https://www.eurekalert.org/news-releases/990464
6. PMC — “Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing” (2025): https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
7. PubMed — “Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295” (2006): https://pubmed.ncbi.nlm.nih.gov/16352683/
8. FDA — “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks”: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
9. PMC — “Bremelanotide for female HSDD” (2022): https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/
10. Harvard Science Review — “The GLP-1 Aftermath: What the Science Says About Muscle Loss and Cellular Aging” (2026): https://harvardsciencereview.org/2026/02/23/the-glp-1-aftermath-what-the-science-says-about-muscle-loss-and-cellular-aging/